Furthermore, in a rat model of endotoxemia, both compounds reduced TNF-α and IL-6 levels by decreasing NF-κB expression in the lung and liver, in addition to counteracting histopathological changes caused by LPS. The gene discussed is NFKB1; the disease is serum lipopolysaccharide activity.